2020
DOI: 10.14260/jemds/2020/278
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Role of Tru-Cut Biopsy in the Diagnosis of Clinically Palpable Breast Lumps

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 15 publications
0
0
0
Order By: Relevance
“…In our study sensitivity and specificity for benign diseases in tru-cut is 100% and 97.1% as compared to 97% and 98.2% in malignant diseases respectively. The documented sensitivity of tru-cut biopsy in benign and malig- 12,13 nant diseases is between 87-99%. The sensitivity of FNAC and tru-cut for benign diseases is almost equal (98.2% vs 100%) in our study while there was major difference in sensitivity between FNAC and tru-cut for malignant diseases (72.7% vs 97%).…”
Section: Discussionmentioning
confidence: 99%
“…In our study sensitivity and specificity for benign diseases in tru-cut is 100% and 97.1% as compared to 97% and 98.2% in malignant diseases respectively. The documented sensitivity of tru-cut biopsy in benign and malig- 12,13 nant diseases is between 87-99%. The sensitivity of FNAC and tru-cut for benign diseases is almost equal (98.2% vs 100%) in our study while there was major difference in sensitivity between FNAC and tru-cut for malignant diseases (72.7% vs 97%).…”
Section: Discussionmentioning
confidence: 99%